Cover Image

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

Bjoern Schwander,1 Simona Ravera,2 Giovanni Giuliani,2 Mark Nuijten,3 Stefan Walzer11Assessment-in-Medicine (AiM) GmbH, Loerrach, Germany; 2Roche SpA, Monza, Italy; 3Ars Accessus Medica, Amsterdam (Jisp), NetherlandsBackground: Lung cancer is the leading cause of cancer deaths worldwide (1.38 millio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Schwander B (Author), Ravera S (Author), Giuliani G (Author), Nuijten M (Author), Walzer S (Author)
Format:	Book
Published:	Dove Medical Press, 2012-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
by: Vergnenègre A, et al.
Published: (2012)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
by: Dongchu Zhou, et al.
Published: (2022)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
by: Matteo Franchi, et al.
Published: (2022)

Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
by: Diego Luigi Cortinovis, et al.
Published: (2023)

First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2023)

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe
by: Verleger K, et al.
Published: (2020)

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
by: Ya-Ning Zhu, et al.
Published: (2024)

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Maojin You, et al.
Published: (2022)

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
by: Raj Hanvesakul, et al.
Published: (2023)

Second-line treatment options in hepatocellular carcinoma
by: Donatella Marino, et al.
Published: (2019)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Cost Comparison of Open and Arthroscopic Treatment Options for SLAP Tears
by: Lambert T. Li, B.A, et al.
Published: (2021)

Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review
by: Tao Wang, et al.
Published: (2023)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008)

Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs
by: Jon Apple, et al.
Published: (2023)

Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component
by: Oliver Ibarrondo, et al.
Published: (2022)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2022)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
by: Mingye Zhao, et al.
Published: (2023)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016)

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
by: Deyan Davidov
Published: (2010)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
by: Isla D, et al.
Published: (2016)

Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
by: Wang Y, et al.
Published: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Cost containment by peer prior authorization program for second line treatment in patients with retinal disease
by: Amir Rosenblatt, et al.
Published: (2021)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
by: Taipale K, et al.
Published: (2017)

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

"Highly Exposed Chinese Herbal Medicine" Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
by: Mingqi Wang, et al.
Published: (2021)

Cost of illness of urothelial bladder cancer in Italy
by: Gerace C, et al.
Published: (2017)

Cost-Effectiveness Analysis of Single-Tooth Rehabilitation Options
by: Manuel Henrique de Medeiros Neto, et al.
Published: (2024)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021)

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
by: Lister J, et al.
Published: (2012)

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical; Pathological and Molecular Aspects of Novel Promising Drugs
by: Umberto Malapelle
Published: (2017)

More than cost‐effectiveness? Applying a second‐stage filter to improve policy decision making
by: Kaying Kan, et al.
Published: (2021)